secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2025-02-28T23:59:59+00:00
Accession:  0000950170-25-030020
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

4DMT reports FY2024 net loss of $160.9M; cash $505M; Phase 3 programs on track
------------------------------------------------------------------------------

- Net loss of $160.9M in 2024 vs $100.8M in 2023; R&D expenses $141.3M (up 46% YoY).
- Cash, cash equivalents and marketable securities of $505M as of Dec 31, 2024, funding operations into 2028.
- Phase 3 4FRONT trials for 4D-150 in wet AMD to initiate March 2025 and Q3 2025; topline data expected H2 2027.
- FDA aligned that a single Phase 3 trial is acceptable for BLA submission of 4D-150 in DME.
- Pipeline focused on 4D-150 (wet AMD, DME) and 4D-710 (CF); paused other programs and terminated early-stage rare disease trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000095017025030020/0000950170-25-030020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000095017025030020/fdmt-20250228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-030020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer